Evidence map›Paper›PMID 31637425›Full record

ArticleNeuro-oncology2020

GRP94 promotes brain metastasis by engaging pro-survival autophagy.

Naiara Santana-Codina, Laia Muixí, Ruben Foj, Rebeca Sanz-Pamplona, Miriam Badia-Villanueva, Agata Abramowicz, Anna Marcé-Grau, Ana María Cosialls, Joan Gil, Ivan Archilla and 4 more

Open access · bronzeAbstract read
In one paragraph

Article in Neuro-oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed, 1 pooled it
1.7field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 1 synthesis or guideline pooled it, 35 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. ATM interaction with GRP94 modulates oncogenic receptor expression and signaling and microglial activation.Proceedings of the National Academy of Sciences of the United States of America · 2025
    Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Review
  11. Mechanisms of Organ-Specific Metastasis of Breast Cancer.Cold Spring Harbor perspectives in medicine · 2023
    Review
  12. Review
  13. Review
  14. Repurposing autophagy regulators in brain tumors.International journal of cancer · 2022
    Review
  15. Article
  16. Article
  17. Review
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors at 7 institutions in 2 countries.

Naiara Santana-CodinaBiological Clues of the Invasive and Metastatic Phenotype Group, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain.
Laia MuixíBiological Clues of the Invasive and Metastatic Phenotype Group, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain.
Ruben FojBiological Clues of the Invasive and Metastatic Phenotype Group, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain.
Rebeca Sanz-PamplonaUnit of Biomarkers and Susceptibility, Oncology Data Analytics Program (ODAP), Catalan Institute of Oncology (ICO), Colorectal Cancer Group, ONCOBELL Program, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain.
Miriam Badia-VillanuevaLaboratory of Molecular and Translational Oncology, Center of Biomedical Research-August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain.
Agata AbramowiczMaria Sklodowska-Curie Institute-Oncology Center, Gliwice, Poland.
Anna Marcé-GrauBiological Clues of the Invasive and Metastatic Phenotype Group, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain.
Ana María CosiallsDepartment of Physiological Sciences, School of Medicine and Health Sciences, Campus Bellvitge, Universitat de Barcelona, Oncobell, Bellvitge Medical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain.
Joan GilDepartment of Physiological Sciences, School of Medicine and Health Sciences, Campus Bellvitge, Universitat de Barcelona, Oncobell, Bellvitge Medical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain.
Ivan ArchillaPathology Department, Center of Biomedical Diagnosis, Hospital Clínic, University of Barcelona, Barcelona, Spain.
Leire PedrosaHematology and Oncology Department, Hospital Clinic Barcelona, IDIBAPS, Barcelona, Spain.
Josep GonzalezDepartment of Neurosurgery Hospital Clinic Barcelona, IDIBAPS Advances in Neurosurgery Research Group, Barcelona, Spain.
Iban AldecoaPathology Department, Center of Biomedical Diagnosis, Hospital Clínic, University of Barcelona, Barcelona, Spain.
Angels SierraBiological Clues of the Invasive and Metastatic Phenotype Group, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain.
Institut d'Investigació Biomédica de Bellvitge · ESHospital Clínic de Barcelona · ESUniversitat de Barcelona · ESConsorci Institut D'Investigacions Biomediques August Pi I Sunyer · ESThe Maria Sklodowska-Curie National Research Institute of Oncology · PLUniversitat Autònoma de Barcelona · ESUniversitat de Vic - Universitat Central de Catalunya · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundGRP94 is a glucose-regulated protein critical for survival in endoplasmic reticulum stress. Expression of GRP94 is associated with cellular transformation and increased tumorigenicity in breast cancer. Specifically, overexpression of GRP94 predicts brain metastasis (BM) in breast carcinoma patients with either triple negative or ErbB2 positive tumors. The aim of this study was to understand if microenvironmental regulation of GRP94 expression might be a hinge orchestrating BM progression.

methodsGRP94 ablation was performed in a BM model BR-eGFP-CMV/Luc-V5CA1 (BRV5CA1) of breast cancer. In vitro results were validated in a dataset of 29 metastases in diverse organs from human breast carcinomas and in BM tissue from tumors of different primary origin. BM patient-derived xenografts (PDXs) were used to test sensitivity to the therapeutic approach.

resultsBMs that overexpress GRP94 as well as tumor necrosis factor receptor-associated factor 2 are more resistant to glucose deprivation by induction of anti-apoptotic proteins (B-cell lymphoma 2 and inhibitors of apoptosis proteins) and engagement of pro-survival autophagy. GRP94 ablation downregulated autophagy in tumor cells, resulting in increased BM survival in vivo. These results were validated in a metastasis dataset from human patients, suggesting that targeting autophagy might be strategic for BM prevention. Indeed, hydroxychloroquine treatment of preclinical models of BM from PDX exerts preventive inhibition of tumor growth (P < 0.001).

conclusionsWe show that GRP94 is directly implicated in BM establishment by activating pro-survival autophagy. Disruption of this compensatory fueling route might prevent metastatic growth.

Indexed as

Brain NeoplasmsMembrane ProteinsAnimalsAutophagyHSP70 Heat-Shock ProteinsHumansNeoplasm Transplantationglucose-regulated proteinsHSP70 Heat-Shock ProteinsMembrane Proteinsautophagybiomarkerbrain metastasisbreast cancerendoplasmic reticulum stressGRP94

Identifiers

PMID31637425
PMCPMC7229259
OpenAlexW2981625282

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.